Ergoteles LLC Avrobio, Inc. Transaction History

Ergoteles LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	SELL	$0.64 - $0.91 $40,220 - $57,188	-62,844 Reduced 57.26%	46,906 $33,000
Q3 2022 Nov 14, 2022	SELL	$0.68 - $1.11 $19,922 - $32,520	-29,298 Reduced 21.07%	109,750 $71,000
Q2 2022 Aug 12, 2022	BUY	$0.75 - $1.33 $104,286 - $184,933	139,048 New	139,048 $128,000
Q4 2021 Feb 14, 2022	SELL	$3.45 - $6.05 $71,839 - $125,979	-20,823 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$5.53 - $9.28 $115,151 - $193,237	20,823 New	20,823 $116,000

559K

Ticker AVRO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,773,900
Description
AVROBIO, Inc., a clinical-stage gene therapy company, develops ex vivo lentiviral-based gene therapies to treat rare diseases following a single dose worldwide. Its gene therapies employ hematopoietic stem cells that are collected from patients and modified with a lentiviral vector to insert functional copies of the gene that is defective in the...

Get notified when there are updates to the investment portfolio of Ergoteles LLC, based on Form 13F filings with the SEC.

Stay updated on Ergoteles LLC with notifications on news.